NCT03882281View on ClinicalTrials.gov

Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 25, 2019

Primary Completion Date

November 16, 2019

Study Completion Date

November 16, 2019

Conditions
Chronic Myeloid Leukemia, Chronic Phase
Interventions
DRUG

HQP1351

Orally, single dose of 30mg on day 1 and day 8.

Trial Locations (1)

100044

Peking University People's Hospital, Beijing

Sponsors
All Listed Sponsors
collaborator

HealthQuest Pharma Inc.

INDUSTRY

lead

Ascentage Pharma Group Inc.

INDUSTRY